Edesa Common Stock Total Equity vs Total Assets Analysis
| EDSA Stock | USD 2.44 0.14 6.09% |
Edesa Biotech financial indicator trend analysis is much more than just examining Edesa Biotech latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edesa Biotech is a good investment. Please check the relationship between Edesa Biotech Common Stock Total Equity and its Total Assets accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.
Common Stock Total Equity vs Total Assets
Common Stock Total Equity vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edesa Biotech Common Stock Total Equity account and Total Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Edesa Biotech's Common Stock Total Equity and Total Assets is 0.44. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Total Assets in the same time period over historical financial statements of Edesa Biotech, assuming nothing else is changed. The correlation between historical values of Edesa Biotech's Common Stock Total Equity and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Edesa Biotech are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Common Stock Total Equity i.e., Edesa Biotech's Common Stock Total Equity and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.44 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Total Assets
Total assets refers to the total amount of Edesa Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Edesa Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Edesa Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 1 B, whereas Selling General Administrative is forecasted to decline to about 3.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 118.2K | 183.5K | 165.1K | 156.9K | Research Development | 13.3M | 4.8M | 5.5M | 4.3M |
Edesa Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Edesa Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edesa Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.8M | 14.6M | 11.6M | 8.9M | 10.2M | 8.7M | |
| Other Current Liab | (69.7K) | 1.4M | (19.0K) | 1.7M | 1.6M | 1.7M | |
| Total Current Liabilities | 1.5M | 1.5M | 2.1M | 1.8M | 2.1M | 1.3M | |
| Total Stockholder Equity | 6.6M | 13.1M | 9.4M | 7.0M | 8.1M | 6.4M | |
| Net Debt | (7.0M) | (7.7M) | (7.1M) | (5.3M) | (4.7M) | (5.0M) | |
| Retained Earnings | (13.1M) | (26.5M) | (44.0M) | (52.4M) | (47.2M) | (44.8M) | |
| Cash | 7.2M | 7.8M | 7.1M | 5.4M | 6.2M | 5.6M | |
| Non Current Assets Total | 2.7M | 2.5M | 2.5M | 2.5M | 2.8M | 3.0M | |
| Cash And Short Term Investments | 7.2M | 7.8M | 7.1M | 5.4M | 6.2M | 6.8M | |
| Common Stock Shares Outstanding | 1.2M | 1.7M | 2.1M | 2.9M | 3.3M | 3.5M | |
| Liabilities And Stockholders Equity | 10.8M | 14.6M | 11.6M | 8.9M | 10.2M | 8.7M | |
| Other Current Assets | 802.9K | 1.9M | 745.5K | 448.9K | 516.2K | 402.8K | |
| Other Stockholder Equity | 1.6M | 4.9M | 11.2M | 13.0M | 15.0M | 15.7M | |
| Total Liab | 4.1M | 1.5M | 2.2M | 1.8M | 2.1M | 2.3M | |
| Total Current Assets | 8.1M | 12.1M | 9.1M | 6.4M | 7.4M | 7.6M | |
| Property Plant And Equipment Net | 174.8K | 111.6K | 31.2K | 100.1K | 90.1K | 85.6K | |
| Net Receivables | 87.4K | 3.3M | 1.3M | 626.5K | 720.5K | 521.2K | |
| Property Plant And Equipment Gross | 174.8K | 145.4K | 70.7K | 143.9K | 129.5K | 123.1K | |
| Accumulated Other Comprehensive Income | (287.2K) | (205.3K) | (213.6K) | (214.6K) | (246.8K) | (234.5K) | |
| Non Current Liabilities Total | 2.6M | 67.7K | 43.7K | 19.8K | 17.8K | 16.9K | |
| Inventory | 224.3K | (217.1K) | (87.4K) | (1.3M) | (1.1M) | (1.1M) | |
| Common Stock | 18.5M | 34.9M | 42.5M | 46.6M | 53.6M | 39.4M | |
| Property Plant Equipment | 73.1K | 174.8K | 111.6K | 31.2K | 28.0K | 26.6K | |
| Accounts Payable | 1.5M | 1.4M | 2.1M | 1.7M | 2.0M | 1.2M | |
| Net Tangible Assets | 5.3M | 4.1M | 10.7M | 7.1M | 8.2M | 4.3M | |
| Net Invested Capital | 6.6M | 13.1M | 9.4M | 7.0M | 8.1M | 9.4M | |
| Net Working Capital | 6.6M | 10.6M | 7.0M | 4.6M | 4.2M | 5.8M | |
| Capital Stock | 18.5M | 34.9M | 42.5M | 46.6M | 53.6M | 38.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.